Press Materials
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »
Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.
Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.
Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor
Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor
Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial
20180105_Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial
Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex on Scandinavian markets
20171130_Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex on Scandinavian markets
Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression
20171128_Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression
Stable business foundation with a good prospect for presence in new European markets.
20171115_ Stable business foundation with a good prospect for presence in new European markets.
Steady income and positive sales dynamics of Celon Pharma S.A. in the first half of 2017
20170920_Steady income and positive sales dynamics of Celon Pharma S.A.
Celon Pharma S.A. submitted an application for a permit to build a Research and Development Centre in Kazuń Nowy.
20170727_Celon Pharma S.A. submitted an application for a permit to build a Research and Development Centre in Kazuń Nowy.